Regulatory MSD’s Keytruda-Padcev combo secures EC approval for MIBC Pharmaceutical Business ReviewThe authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy.OncologyRead full story pharminent June 25, 2026 (Last updated: June 25, 2026) Pharmaceutical Business Review The authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy. Oncology Read full story Post navigation Previous: Lilly launches its LillyDirect sales channel in the UKNext: FDA’s uniQure, REGENXBIO reversals could bolster other near-term rare disease applications Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026